Citigroup Inc. Sells 2,390 Shares of Medpace Holdings, Inc. $MEDP

Citigroup Inc. reduced its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.4% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 96,646 shares of the company’s stock after selling 2,390 shares during the quarter. Citigroup Inc. owned 0.34% of Medpace worth $49,692,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Fifth Third Wealth Advisors LLC increased its position in shares of Medpace by 2.6% in the third quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock worth $379,000 after purchasing an additional 19 shares during the last quarter. HighPoint Advisor Group LLC grew its stake in Medpace by 2.8% in the 3rd quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock worth $416,000 after buying an additional 22 shares in the last quarter. Portside Wealth Group LLC increased its holdings in shares of Medpace by 2.5% in the 2nd quarter. Portside Wealth Group LLC now owns 1,090 shares of the company’s stock worth $342,000 after buying an additional 27 shares during the last quarter. Whittier Trust Co. of Nevada Inc. raised its position in shares of Medpace by 35.1% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock valued at $55,000 after buying an additional 27 shares in the last quarter. Finally, M&T Bank Corp raised its position in shares of Medpace by 3.4% during the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after buying an additional 31 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Insider Activity at Medpace

In related news, CEO August J. Troendle sold 41,331 shares of Medpace stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $606.88, for a total value of $25,082,957.28. Following the transaction, the chief executive officer directly owned 690,879 shares of the company’s stock, valued at $419,280,647.52. The trade was a 5.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold 80,328 shares of company stock valued at $48,219,399 over the last quarter. 20.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

MEDP has been the subject of several research reports. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Leerink Partners cut their price objective on Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a report on Wednesday, February 11th. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and dropped their target price for the stock from $462.00 to $419.00 in a research report on Wednesday, February 18th. Finally, Barclays cut their target price on Medpace from $525.00 to $500.00 and set an “underweight” rating for the company in a research note on Wednesday, February 11th. Four investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $483.45.

Medpace Trading Down 1.9%

MEDP opened at $444.96 on Tuesday. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $628.92. The business’s 50-day moving average price is $553.73 and its 200-day moving average price is $539.55. The company has a market cap of $12.63 billion, a P/E ratio of 29.08, a P/E/G ratio of 2.17 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. During the same period last year, the company earned $3.67 EPS. Medpace’s revenue for the quarter was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.